NHE3 blockade impaired SGLT1‐mediated intestinal glucose absorption through serum/glucocorticoid regulated kinase 1(SGK1) and improved glucose intolerance in diabetic mice, proposing the NHE3‐SGLT1 signalling axis, potential clinical use of NHE3 blockers in reducing intestinal glucose uptake and counteracting postprandial glucose levels in patients with T2DM.90 The gene discussed is SLC9A3; the disease is type 2 diabetes mellitus.